Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W P Steward

Showing results (71-80 of 129) with videos related to

Pageof 13
Sort By:
Annals of the Royal College of Surgeons of England|March 31, 2007
A review of phase III clinical trials of prostate cancer chemopreventionJ F Thorpe, S Jain, T H Marczylo, et al.
European Journal of Cancer & Clinical Oncology|October 1, 1985
A prospective study of the treatment of high-grade histology non-Hodgkin's lymphoma involving the gastrointestinal tractW P Steward, M Harris, J Wagstaff, et al.
British Journal of Cancer|May 1, 1990
Granulocyte-macrophage colony stimulating factor (GM-CSF) after high-dose melphalan in patients with advanced colon cancerW P Steward, J H Scarffe, L Y Dirix, et al.
British Journal of Cancer|November 1, 1994
Filgrastim fails to improve haemopoietic reconstitution following myeloablative chemotherapy and peripheral blood stem cell rescueD J Dunlop, E J Fitzsimons, A McMurray, et al.
European Journal of Cancer (Oxford, England : 1990)|August 11, 2006
Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignanciesR A Sharma, W P Steward, C A Daines, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 26, 2001
Clinical development of leukocyte cyclooxygenase 2 activity as a systemic biomarker for cancer chemopreventive agentsS M Plummer, K A Hill, M F Festing, et al.
British Journal of Cancer|June 27, 2002
A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancerK J O'Byrne, A L Thomas, R A Sharma, et al.
European Journal of Cancer (Oxford, England : 1990)|February 1, 1990
Doxorubicin in relapsed soft tissue sarcoma: justification of phase II evaluation of new drugs in this disease. An EORTC Soft Tissue and Bone Sarcoma Group StudyG Blackledge, A van Oosterom, H Mouridsen, et al.
Ciba Foundation Symposium|January 1, 1990
Growth factor-assisted chemotherapy--the Manchester experienceD Crowther, J H Scarffe, A Howell, et al.
Cancer|September 15, 1985
Three months' treatment with cyclophosphamide, VP-16-213 followed by methotrexate and thoracic radiotherapy for small cell lung cancerN Thatcher, R D James, W P Steward, et al.
Pageof 13

Showing results (71-80 of 129) with videos related to

Sort By:
Pageof 13
Annals of the Royal College of Surgeons of England|March 31, 2007
A review of phase III clinical trials of prostate cancer chemopreventionJ F Thorpe, S Jain, T H Marczylo, et al.
European Journal of Cancer & Clinical Oncology|October 1, 1985
A prospective study of the treatment of high-grade histology non-Hodgkin's lymphoma involving the gastrointestinal tractW P Steward, M Harris, J Wagstaff, et al.
British Journal of Cancer|May 1, 1990
Granulocyte-macrophage colony stimulating factor (GM-CSF) after high-dose melphalan in patients with advanced colon cancerW P Steward, J H Scarffe, L Y Dirix, et al.
British Journal of Cancer|November 1, 1994
Filgrastim fails to improve haemopoietic reconstitution following myeloablative chemotherapy and peripheral blood stem cell rescueD J Dunlop, E J Fitzsimons, A McMurray, et al.
European Journal of Cancer (Oxford, England : 1990)|August 11, 2006
Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignanciesR A Sharma, W P Steward, C A Daines, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 26, 2001
Clinical development of leukocyte cyclooxygenase 2 activity as a systemic biomarker for cancer chemopreventive agentsS M Plummer, K A Hill, M F Festing, et al.
British Journal of Cancer|June 27, 2002
A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancerK J O'Byrne, A L Thomas, R A Sharma, et al.
European Journal of Cancer (Oxford, England : 1990)|February 1, 1990
Doxorubicin in relapsed soft tissue sarcoma: justification of phase II evaluation of new drugs in this disease. An EORTC Soft Tissue and Bone Sarcoma Group StudyG Blackledge, A van Oosterom, H Mouridsen, et al.
Ciba Foundation Symposium|January 1, 1990
Growth factor-assisted chemotherapy--the Manchester experienceD Crowther, J H Scarffe, A Howell, et al.
Cancer|September 15, 1985
Three months' treatment with cyclophosphamide, VP-16-213 followed by methotrexate and thoracic radiotherapy for small cell lung cancerN Thatcher, R D James, W P Steward, et al.
Pageof 13